Renal failure after allogeneic hematopoietic stem cell transplantation : Recommendations of the Francophone Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)
Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved..
Acute and chronic renal failures are very common after allogeneic HSCT. These complications have a real impact on mortality and morbidity of transplant recipients. Within the framework of the ninth workshops of practice harmonization of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) held in Lille in September 2018, various causes and mechanisms of renal failure, diagnostic work-up, treatment and recommendations to limit renal failure after transplantation are reviewed. Recommendations to adjust medications to avoid renal failure are also proposed in this article.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
Bulletin du cancer - 107(2020), 1S vom: 23. Jan., Seite S28-S35 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Insuffisance rénale et allogreffe de cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) |
|---|
| Beteiligte Personen: |
Detrait, Marie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.03.2020 Date Revised 03.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bulcan.2019.05.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299162818 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299162818 | ||
| 003 | DE-627 | ||
| 005 | 20231225095737.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.bulcan.2019.05.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0997.xml |
| 035 | |a (DE-627)NLM299162818 | ||
| 035 | |a (NLM)31303250 | ||
| 035 | |a (PII)S0007-4551(19)30226-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Detrait, Marie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Renal failure after allogeneic hematopoietic stem cell transplantation |b Recommendations of the Francophone Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC) |
| 246 | 3 | 3 | |a Insuffisance rénale et allogreffe de cellules souches hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2020 | ||
| 500 | |a Date Revised 03.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Acute and chronic renal failures are very common after allogeneic HSCT. These complications have a real impact on mortality and morbidity of transplant recipients. Within the framework of the ninth workshops of practice harmonization of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) held in Lille in September 2018, various causes and mechanisms of renal failure, diagnostic work-up, treatment and recommendations to limit renal failure after transplantation are reviewed. Recommendations to adjust medications to avoid renal failure are also proposed in this article | ||
| 650 | 4 | |a Consensus Development Conference | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Allogeneic hematopoietic stem cell transplantation | |
| 650 | 4 | |a Allogreffe de cellules souches hématopoïétiques | |
| 650 | 4 | |a Complications rénales | |
| 650 | 4 | |a Renal complications | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a de Berranger, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Dulery, Remy |e verfasserin |4 aut | |
| 700 | 1 | |a Ménard, Anne-Lise |e verfasserin |4 aut | |
| 700 | 1 | |a Thépot, Sylvain |e verfasserin |4 aut | |
| 700 | 1 | |a Toprak, Selami Kocak |e verfasserin |4 aut | |
| 700 | 1 | |a Turlure, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Yakoub-Agha, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Guillaume, Thierry |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g 107(2020), 1S vom: 23. Jan., Seite S28-S35 |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2020 |g number:1S |g day:23 |g month:01 |g pages:S28-S35 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bulcan.2019.05.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2020 |e 1S |b 23 |c 01 |h S28-S35 | ||